A Randomized, Double-blind, Placebo-controlled Study to Determine Whether Chronic Treatment of Cystic Fibrosis Subjects With Impaired Glucose Tolerance Using Sitagliptin (Januvia) Prevents the Development of Diabetes.

Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Determine Whether Chronic Treatment of Cystic Fibrosis Subjects With Impaired Glucose Tolerance Using Sitagliptin (Januvia) Prevents the Development of Diabetes.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 16 May 2017

At a glance

  • Drugs Sitagliptin (Primary)
  • Indications Diabetes mellitus; Glucose intolerance
  • Focus Therapeutic Use
  • Acronyms Prevent
  • Most Recent Events

    • 10 May 2017 Planned End Date changed from 1 Mar 2019 to 31 Dec 2017.
    • 10 May 2017 Status changed from recruiting to discontinued.
    • 18 Apr 2016 Planned End Date changed from 1 Mar 2017 to 1 Mar 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top